

Drug-Resistant Infections & the Immediate and Future Demand for Novel Antimicrobials

Duke-Margolis Center for Health Policy

Webinar Agenda | Tuesday, May 9, 2023 | 2:00 – 3:00 pm ET

About the Webinar

Duke-Margolis invites policymakers, legislative advisors, and others interested in addressing emerging infectious diseases—including drug-resistant infections and antimicrobial resistance (AMR)—to learn about the clinical and public health impact of drug-resistant infections and why policymakers are proposing new incentives for novel antimicrobials. Expert speakers will highlight:

- The current and future threat of drug-resistant infections and antimicrobial resistance
- Market uncertainties that complicate antimicrobial development and commercialization
- Existing and proposed incentives for novel antimicrobials, including the PASTEUR Act

Discussion will inform policy approaches that decision-makers can leverage to improve the clinical impact, availability, and stewardship of novel antimicrobials.

2:00 pm **Welcome and Opening Remarks**

Mark McClellan, Director, Duke-Margolis Center for Health Policy

A Conversation with U.S. Senator Todd Young: Addressing the Threat of Drug-Resistant Infections

Effective antimicrobials treat a range of infections and enable clinicians to provide care that might otherwise result in dangerous infections. Unfortunately, the development and spread of antimicrobial resistance (AMR) and drug-resistant infections poses a severe and growing threat to us all.

To address this threat, policymakers are carefully considering how to meet immediate and future demand for novel antimicrobials with thoughtful market incentives under challenging circumstances.

Senator Todd Young, United States Senate

Mark McClellan, Duke-Margolis Center for Health Policy

The Value of Novel Antimicrobials and Pull Incentives to Encourage Antimicrobial Development and Availability

Moderator: Mark McClellan

Antimicrobials are particularly valuable because they treat and prevent infections, enable medical procedures like surgery, and prepare health systems to address emerging infectious diseases.

To combat drug-resistant infections and counter antimicrobial resistance (AMR), clinicians rely on antimicrobials and the knowledge to prescribe them. However, challenging research and clinical circumstances complicate novel antimicrobial development and antimicrobial stewardship.

In a moderated question and answer format, panelists will discuss:

- The impact of drug-resistant infections in the U.S. and around the world
- The value of antimicrobials to individuals and populations
- Momentum toward pull incentives and international policy alignment
- Tailored incentives and support for antimicrobial stewardship and access

Panelists

- **Helen Boucher**, Tufts University School of Medicine
- **Michael Craig**, Centers for Disease Control and Prevention
- **Annukka Ojala**, European Commission
- **Henry Skinner**, AMR Action Fund

Closing Remarks

Mark McClellan

3:00 pm Adjournment